Prestige Consumer Healthcare Reports Record Fiscal 2025 Results

Prestige Consumer Healthcare ( (PBH) ) has released its Q4 earnings. Here is a breakdown of the information Prestige Consumer Healthcare presented to its investors.

Prestige Consumer Healthcare Inc. is a prominent player in the consumer healthcare sector, offering a diverse range of over-the-counter products across North America and international markets. The company’s portfolio includes well-known brands such as Monistat, Summer’s Eve, and Dramamine.

In its latest earnings report, Prestige Consumer Healthcare announced record revenue and earnings for fiscal 2025, with total revenue reaching $1,137.8 million and a diluted EPS of $4.29. The company highlighted strong performance in both North American and International segments, driven by growth in the gastrointestinal and women’s health categories.

Key financial metrics revealed a 7.9% organic revenue growth in Q4 and a 1.2% increase for the fiscal year, excluding foreign currency impacts. The company also reported a reduction in leverage to 2.4x, supported by robust free cash flow and EBITDA growth. Strategic initiatives included share repurchases and a focus on M&A activities.

Looking ahead, Prestige Consumer Healthcare anticipates organic revenue growth of 1% to 2% and a diluted EPS of $4.70 to $4.82 for fiscal 2026. The company aims to leverage its diverse product portfolio and agile operating model to navigate inflationary pressures and continue delivering consistent financial results.

Overall, Prestige Consumer Healthcare remains committed to executing its strategic plans, maintaining a strong balance sheet, and enhancing shareholder value through disciplined capital allocation and operational efficiency.